1. Home
  2. XTNT vs ACRV Comparison

XTNT vs ACRV Comparison

Compare XTNT & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xtant Medical Holdings Inc.

XTNT

Xtant Medical Holdings Inc.

HOLD

Current Price

$0.47

Market Cap

68.9M

Sector

Health Care

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.62

Market Cap

82.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XTNT
ACRV
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.9M
82.2M
IPO Year
2009
2022

Fundamental Metrics

Financial Performance
Metric
XTNT
ACRV
Price
$0.47
$1.62
Analyst Decision
Strong Buy
Buy
Analyst Count
1
4
Target Price
$1.00
$11.67
AVG Volume (30 Days)
150.9K
493.5K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
125.00
15.13
EPS
N/A
N/A
Revenue
$53,337,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$9.30
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$1.05
52 Week High
$0.95
$3.56

Technical Indicators

Market Signals
Indicator
XTNT
ACRV
Relative Strength Index (RSI) 39.92 40.40
Support Level $0.44 $1.51
Resistance Level $0.67 $1.86
Average True Range (ATR) 0.03 0.12
MACD -0.00 -0.03
Stochastic Oscillator 19.73 7.61

Price Performance

Historical Comparison
XTNT
ACRV

About XTNT Xtant Medical Holdings Inc.

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: